ANZBMS 2026 Meet the NEW anabolic - Eladynos: from science to patient selection
Join Theramex and an esteemed panel of experts for an interactive lunchtime symposium exploring the clinical rationale for Eladynos (abaloparatide), with practical insights into identifying, selecting, and initiating appropriate patients at increased risk of fracture*. Through expert discussion and real-world perspectives, attendees will gain guidance to support confident treatment decisions in clinical practice.
*ELADYNOS is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. Eladynos must be initiated by a consultant physician. Continuing therapy must be treated by a medical practitioner identifying as either: (i) a consultant physician, (ii) a general practitioner.
Symposia Agenda
Welcome & Introductions - Theramex
The Science: Why Abaloparatide? - Professor Bente Langdahl, Aarhus University Hospital, Denmark
Case Study 1 - Professor Jackie Center, St. Vincent's Hospital, Sydney
Case Study 2 - Dr. Jasna Aleksova, Hudson Institute/Monash Health, Melbourne
Case Study 3 - Dr. Shoshana Sztal-Mazer, The Alfred Hospital, Melbourne
Interactive Panel Discussion & Q&A